• 1. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 2. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 3. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 4. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 5. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidolactams Imidolactams
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidolactams

Recent Advances in the Study of 3-Cyclopropyl-1H-pyrazol-5-amine hydrochloride (CAS: 1031791-16-8)

3-Cyclopropyl-1H-pyrazol-5-amine hydrochloride (CAS: 1031791-16-8) is a chemical compound that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its pyrazole core and cyclopropyl substituent, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and potential as a building block for more complex drug molecules. The compound's unique structural features make it a valuable candidate for further exploration in drug discovery and development.

One of the key areas of research involving 3-Cyclopropyl-1H-pyrazol-5-amine hydrochloride is its role as an intermediate in the synthesis of biologically active molecules. Recent publications have highlighted its utility in the preparation of kinase inhibitors, which are crucial in the treatment of cancers and inflammatory diseases. The compound's ability to act as a versatile scaffold has been demonstrated in several synthetic routes, enabling the development of novel compounds with enhanced efficacy and selectivity. Researchers have also investigated its pharmacokinetic properties, including solubility and stability, to optimize its use in drug formulations.

In addition to its synthetic applications, 3-Cyclopropyl-1H-pyrazol-5-amine hydrochloride has been studied for its direct biological effects. Preliminary in vitro and in vivo studies suggest that the compound exhibits moderate activity against certain enzyme targets, such as cyclin-dependent kinases (CDKs) and Janus kinases (JAKs). These findings have spurred further investigations into its mechanism of action and potential therapeutic benefits. Recent advancements in computational modeling and high-throughput screening have also facilitated the identification of derivative compounds with improved binding affinities and reduced off-target effects.

The safety and toxicological profile of 3-Cyclopropyl-1H-pyrazol-5-amine hydrochloride have been another focal point of recent research. Studies conducted on animal models have provided valuable insights into its acute and chronic toxicity, as well as its metabolic pathways. These data are critical for assessing the compound's suitability for clinical development. Furthermore, efforts to scale up its synthesis under Good Manufacturing Practice (GMP) conditions have been reported, indicating progress toward its potential use in large-scale pharmaceutical production.

Looking ahead, the continued exploration of 3-Cyclopropyl-1H-pyrazol-5-amine hydrochloride and its derivatives holds great promise for the discovery of new therapeutic agents. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of these findings into clinical applications. Future research directions may include the optimization of its chemical structure for enhanced bioavailability and the exploration of its potential in combination therapies. As the body of evidence grows, this compound is poised to play a pivotal role in the advancement of chemical biology and drug development.

• 175137-46-9(3-Cyclopropyl-1H-pyrazol-5-amine)
• 110086-14-1(3-(Heptan-3-yl)-1H-pyrazol-5-amine)
• 81542-54-3(5-Cyclohexyl-1H-pyrazol-3-amine)
• 56367-25-0(3-(butan-2-yl)-1H-pyrazol-5-amine)
• 326827-21-8(3-cyclobutyl-1H-pyrazol-5-amine)
• 126748-58-1(5-Propyl-1H-pyrazol-3-ylamine)
• 81114-33-2(3-(pentan-3-yl)-1H-pyrazol-5-amine)
• 264209-16-7(5-cyclopentyl-1H-pyrazol-3-amine)
• 110086-20-9(1H-Pyrazol-3-amine, 5-(1,1-dimethylpropyl)-)
• 852443-64-2(5-Cyclopropylmethyl-2H-pyrazol-3-ylamine)